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The existence of stem cells in human amniotic ﬂuid was reported for the ﬁrst time almost ten years ago. Since this discovery,
the knowledge about these cells has increased dramatically. Today, amniotic ﬂuid stem (AFS) cells are widely accepted as a new
powerful tool for basic research as well as for the establishment of new stem-cell-based therapy concepts. It is possible to generate
monoclonal genomically stable AFS cell lines harboring high proliferative potential without raising ethical issues. Many diﬀerent
groups have demonstrated that AFS cells can be diﬀerentiated into all three germ layer lineages, what is of relevance for both, the
scientiﬁc and therapeutical usage of these cells. Of special importance for the latter is the fact that AFS cells are less tumorigenic
than other pluripotent stem cell types. In this paper, we have summarized the current knowledge about this relatively young
scientiﬁc ﬁeld. Furthermore, we discuss the relevant future perspectives of this promising area of stem cell research focusing on
the next important questions, which need to be answered.
1.Introduction
Although human amniotic ﬂuid cells are widely used in
routine prenatal diagnosis, the knowledge about these cells
remains limited. However, the notion that undiﬀerentiated
and diﬀerentiated cells of varying origins and lineages are
present in amniotic ﬂuid has been supported by several
reports over the last three decades. This is not surprising,
considering that cells belonging to the amniotic epithelium,
fetal skin, and the fetal urogenital, respiratory, and gas-
trointestinal systems have been detected in amniotic ﬂuid.
During prolonged gestation, fetal respiratory, urine, and gut
secretions can be found in the amniotic ﬂuid. In addition, it
is also known that the composition, the morphology, and the
growth properties of amniotic-ﬂuid cell samples are aﬀected
by certain fetal pathologies, such as for example, neural tube
defects or gastroschisis [1–3].
New interest in amniotic ﬂuid-derived cells was initiated
by two independent ﬁndings. In 2001, it was suggested that
amniotic ﬂuid cells could be used in tissue engineering ap-
proaches for the surgical repair of congenital anomalies in
the perinatal period. The authors mechanically isolated a
subpopulation of cells from amniotic ﬂuid of pregnant ewes
with a distinct morphology. The immunocytochemical
proﬁle of these cells was very comparable to that of cells of
a mesenchymal, ﬁbroblast/myoﬁbroblast lineage. Exhibiting
signiﬁcantly faster proliferation than comparable fetal and
adult cells, these amniotic ﬂuid-derived cells could be culti-
vated on polyglycolic acid polymer scaﬀolds up to conﬂuent
cell layers [4]. It has originally been discussed that such an
engineered construct would be optimal to function as a graft
for implantation either in the neonatal period or even before
birth. This could be of special interest for children born
with a body wall defect, who are too young for a graft to
be taken from elsewhere in their bodies for reconstructive
surgery [4, 5]. The results obtained in animal models are
indeed encouraging. However, to the best of our knowledge,
wearenotawareofareportdescribingtheclinicaluseofsuch
a cell-based therapy approach in humans until now.
Another ﬁnding on amniotic ﬂuid cells initiated a very
promising and rapidly growing research ﬁeld. Almost ten
years ago, the ﬁrst suggestion of human amniotic ﬂuid as a
new putative source for stem cells was published [5–7]. The
ﬁrst evidence for the existence of AFS cells was demonstrated
by the discovery of a highly proliferative cell type in
human amniotic ﬂuid expressing the pluripotent stem cell
marker Oct4. Beside the fact that these cells express markers
known to be speciﬁc for pluripotent stem cells, they were2 Stem Cells International
proven to express cell cycle proteins known to be speciﬁc
for cycling cells [5–8]. After this ﬁrst description, many
groups have conﬁrmed the existence of these Oct4+/c-Kit+
AFS cells and have reported their potential to diﬀerentiate
into hematopoietic, neurogenic, osteogenic, chondrogenic,
adipogenic, renal, hepatic, and various other lineages [9–
19]. Although, regarding their biological properties and
marker expression pattern, AFS cells appear to be more
similar to embryonic stem (ES) cells than, for example, to
trophoblast cells, the precise origin of AFS cells remains
elusive. Biochemical, immunocytochemical, biological, and
morphological investigations revealed that AFS cells repre-
sent a new and speciﬁc entity, being distinct from ES cells or
other stem cell types, such as the ones which can be isolated
from amniotic epithelial or trophoblastic sources. Today it is
of great interest to clarify two relevant questions with regard
to AFS cells. Where do they come from? Do they have an in
vivo biological function? We have already earlier discussed
that AFS cells could probably play a role in intrauterine
wound healing processes. However, so far there exists no
experimental support for this hypothesis. It is obvious that
experimental settings allowing to prove this hypothesis are
not really easy to imagine or practical at this time (or yet to
be developed) [9–19].
Since their ﬁrst discovery, it was of highest importance to
clarifythequestionwhetherAFScellsreallyharbourpluripo-
tent diﬀerentiation potential via successfully initiating the
diﬀerentiationintodiﬀerentlineagesstartingfromonesingle
stem cell. It is relevant to note that many diﬀerent reports
in the literature claiming to describe research on AFS cells
did not even clarify what kind of cells they are working with.
Quiteoften,theinvestigatorsjustusedamixtureofcellsfrom
amniotic ﬂuid obtained via speciﬁc cultivation procedures.
However, as mentioned above, such amniotic-ﬂuid-derived
cell mixtures contain a wide variety of speciﬁc undiﬀerenti-
ated and diﬀerentiated cell types. Whenever a study reports
ad i ﬀerentiation potential upon speciﬁc cell lineages, it is
of highest relevance to ﬁrst clarify which starting cell type
was used (by detailed biological and immunocytochemical
characterization). Furthermore, the proof that AFS cells
really harbour pluripotent diﬀerentiation potential can only
be obtained starting with one single cell characterized to
be a stem cell. In any other case, one could assume that
a mixture of amniotic ﬂuid cells, which has been used
as starting material, very likely contained a cell type with
the potential to diﬀerentiate into a speciﬁc lineage and
other cell types with other diﬀerentiation potentials. Or the
used in vitro diﬀerentiation protocol used in some studies
induced a selection (via a growth advantage) for an already
(included) diﬀerentiated cell type rather than the bona ﬁde
diﬀerentiation. Single cell approaches are obligatory and
practical after minimal dilution experiments.
The ﬁrst research group, which was really taking that
into account, reported that descending from one single
Oct4-positive AFS cell, it was possible to induce adipogenic,
osteogenic, and neurogenic diﬀerentiation [10]. The authors
used a two-stage culture protocol followed by a detailed
immunocytochemical characterization of the obtained stem
cell type [10]. Three years later, another research group
isolated monoclonal AFS cells via ﬂow cytometric selection
and minimal dilution, which expressed the stem cell mark-
ers c-Kit and Oct4 [14]. The authors described the ﬁrst
establishment of monoclonal AFS cell lines, harbouring a
high proliferative potential, which could be cultivated for
many cycling periods with a stable chromosomal status.
Using such AFS cell lines allowed them to demonstrate that
adipogenic, osteogenic, myogenic, endothelial, neurogenic
and hepatic cell diﬀerentiation could be induced. Impor-
tantly, these authors also reported that AFS cells, unlike ES
cells, do not induce tumor formation in severe combined
immunodeﬁcient (SCID) mice (for a detailed discussion of
this aspect see below) [14].
ES cells, when cultivated in the absence of diﬀeren-
tiation factors, can spontaneously form three-dimensional
multicellular aggregates called embryoid bodies. In the past,
embryoid bodies have been widely considered as an optimal
startingpointforthediﬀerentiationofstemcellsintovarious
lineages. Accordingly, embryoid body formation followed
by diﬀerent diﬀerentiation-inducing approaches is seen as
an appropriate way to prove the pluripotent diﬀerentiation
potential of a speciﬁc stem cell type [8, 20]. Consequently, it
was of interest to test whether, starting from one single cell,
AFS cells are capable of forming embryoid bodies. Indeed,
monoclonal human AFS cells can form embryoid bodies,
when cultured without antidiﬀerentiation factors under
conditions in which they are unable to attach to the surface
of culture dishes and without contact to feeder cells. The for-
mation of such three-dimensional multicellular aggregates is
accompanied by a decrease of stem cell marker expression
and by the induction of diﬀerentiation into diﬀerent lin-
eages [20]. This study demonstrating the potential to form
embryoid bodies was the ultimative proof of AFS cells to be
pluripotent. In addition, it now allows the recapitulation and
investigation of the three-dimensional structures and tissue-
level contexts of many diﬀerentiation phenomena during
early mammalian embryogenesis [20]. These ﬁndings on the
pluripotency of AFS cells were obtained using monoclonal
cell lines generated via magnetic cell sorting and minimal
dilution approaches from human amniocentesis samples.
Today, many diﬀerent established monoclonal lines exist,
which can be expanded as immature stem cells with high
proliferation rate in culture without the need of feeder cells
[14, 20, 21].
Taken together, the current status of knowledge is that
AFS cells harbour the potential to diﬀerentiate into cell types
of the three germ layers (ectoderm, mesoderm, and endo-
derm) and can form embryoid bodies, known as the prin-
cipal step in the diﬀerentiation of pluripotent stem cells.
Compared to other types of stem cells, such as adult stem
cells, ES cells, or induced pluripotent stem (iPS) cells, AFS
cells, have speciﬁc advantages. Adult stem cells are often
hard to sample, exhibit lower diﬀerentiation potential than
AFS cells and cannot be grown with high proliferative
activity. The generation of ES cell lines via destroying a
human embryo raises a variety of ethical issues, which are
discussed diﬀerently from country to country. Furthermore,
ES cells are tumorigenic, whereas AFS cells, as already
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combined immunodeﬁcient mice. Compared to iPS cells,
there is no need for ectopic induction of pluripotency in
AFS cells. AFS cells are genomically stable and do neither
harbour the epigenetic memory nor somatic mutations of
alreadydiﬀerentiatedsourcecells.FurthermoreiPScellshave
been reported to accumulate karyotypic abnormalities and
gene mutations during propagation in culture. Recently,
it has been reported that during the ectopic induction of
pluripotency iPS cells only incompletely recapitulate their
epigenetic pattern. This important ﬁnding must be taken
into account when these cells are planned to be used for
detailed investigations on diﬀerentiation processes as well
as when they are considered for new putative therapeutic
approaches.AFScellsalreadyexhibitstemcellpropertiesand
do not need ectopic induction of pluripotency. Furthermore,
AFS cells already exhibit the epigenetic pattern of stem cells.
In summary, it is not surprising that many attempts are
currently focusing on the question under which conditions
AFS cells could be used for stem-cell-based therapies. Fur-
thermore, AFS cells are currently becoming increasingly
accepted as an optimal tool for basic research [3, 8, 22–24].
Although ES cells, iPS cells, and AFS cells are con-
sidered to harbour a pluripotent diﬀerentiation potential,
the question of whether they exhibit the same qualitative
spectrum of diﬀerentiation potential remains unanswered.
Pluripotent stem cells are deﬁned as self-replicating cells (the
cells can divide per se) known to have the capacity to develop
into cells and tissues of the primary germ layers, ectoderm,
mesoderm, and endoderm. These three stem cell types (ES,
iPS, and AFS cells) have been demonstrated to harbour the
potential to diﬀerentiate into cells of the three germ layers.
All three can also form embryoid bodies. However, whether
they really have comparable potentials to diﬀerentiate into
a speciﬁc cell type with all its known biological functions
must be tested from case to case. In fact, we believe
that it is necessary to directly examine and compare their
diﬀerentiation potentials and select the most suitable cell
types for basic science projects and for the putative usage
in new stem-cell-based therapies. Furthermore, one obvious
diﬀerence between these three pluripotent stem cell types
should be investigated in more detail in future. Since the ﬁrst
description of their in vitro cultivation, ES cells have been
known to be tumorigenic. Similarly, iPS cells induce tumor
formation, when they are subcutaneously transplanted into
nude mice. However, AFS cells have been reported not to
form tumors in severe combined immunodeﬁcient mice.
Since the latter has so far only been studied in one project
analysing a speciﬁc set of animal transplantations, further
investigations are warranted to clarify whether AFS cells are
really not tumorigenic. Obviously, if it holds true, this would
be an important advantage over ES and iPS cells at least with
respect to a putative clinical usage [3, 8, 14, 19, 22–25].
2. AFS Cells for Therapy: FuturePerspectives
Much of the excitement surrounding human stem cells is
connected with the hope of clinicians and patients that these
cells can once be used for cell therapies for a wide spectrum
of human diseases. Here it must clearly be stated that the
work on AFS cell-based therapies is still in its infancy. Many
questions are currently under investigation, and so far no
therapeutic approach based on AFS cells has reached the
level of clinical routine application. However, a variety of
new research results provide strong evidence that AFS cells
could indeed serve a powerful tool in regenerative medicine
[3, 8, 24, 25].
For example, acute and chronic renal failures are dis-
orders with high rates of morbidity and mortality. Kidney
transplantation remains the most eﬀective treatment option
for a majority of patients with end-stage renal disease.
Unfortunately, shortage of compatible organs is a very
limiting factor. Treatment strategies are also based upon
conventional renal dialysis, but the mortality rate of patients
requiring chronic dialysis is high. Accordingly, the putative
usage of stem cells in the repair of kidney injury came
into focus. Several recently published studies on renal
diﬀerentiation of AFS cells make it tempting to speculate
that these stem cells could once be considered as a new
promising source for cell-based therapies to repair kidney
injury and warrant further investigations into this direction
[24, 26–30]. Using a kidney reaggregation assay, we have
recently published that AFS cells harbour the potential
to diﬀerentiate upon nephrogenic lineages and that this
capacity depends on the mammalian target of rapamycin
(mTOR) signalling pathway [28] (see also the discussion
below). Others have demonstrated that human AFS cells
can integrate into renal tissues when injected into isolated
murine embryonic kidneys [27] or that injection of AFS cells
into damaged kidneys of mice with rhabdomyolysis-related
acute tubular necrosis can mediate a protective eﬀect [29].
Although these and other data make it tempting to speculate
that AFS cells may provide successful alternative approaches
for the treatment of, for example, acute tubular necrosis,
many more questions must be answered before such cell-
based therapies can be considered for routine applications in
humans.
For many diﬀerent reasons the establishment of new
stem-cell-based therapies for heretofore incurable central
nervous system pathologies, such as Parkinson’s disease,
spinal cord injury, multiple sclerosis, or stroke, is also of
great interest. Neural stem cells, which have been investi-
gated for this purpose, can be found in the adult central
nervous system and in the developing embryo, but these
tissues are not easily available and raise ethical concerns.
In the recent years, diﬀerent groups have reported on the
neurogenic differentiation potential of AFS cells. However,
before the next steps into the direction of the clinical
usage of AFS cell-based approaches can be considered, the
proof that AFS really can form mature neurons must be
provided. In fact, there is still an ongoing debate in the
literature, discussing whether AFS cells are really able to
form functional neurons. In the near future, it will be very
important to ﬁnd out what kind of neurogenic cell types
can be developed from AFS cells. The question whether AFS
cells can diﬀerentiate into functional mature neurons must
be investigated by analysing the ability to ﬁre tetrodotoxin-
sensitive action potentials with the characteristic shape and4 Stem Cells International
duration or by demonstrating synaptic communication by
electron microscopy [10, 13–16, 18, 19, 31].
Here, it would be possible to discuss some more exam-
ples for putative therapeutic approaches using AFS cells.
Sometimes it is argued that many basic questions regarding
the origin, the tumorigenicity, the diﬀerentiation potential,
the epigenetic status, or the genomic stability must be
investigated before AFS cells could further be considered as a
therapeutictool. However,webelieve allthese aspectsshould
be studied in parallel. In addition, for future considerations
it is really important to quantitatively and qualitatively
compare all these properties of AFS cells to those of other
pluripotent or adult stem cell types.
3.AFSCellsinBasicScience:
Future Perspectives
Stem cells are very useful tools to study the molecular and
cellularregulationofdiﬀerentiationprocesses.Oneapproach
to learn more about the role of, for example, a speciﬁc
gene for a certain diﬀerentiation process is to knock down
the endogenous expression of the gene of interest. Such
an approach allows to clarify the role of modulated gene
expression for the cell potential to diﬀerentiate into a speciﬁc
lineage.We recentlypublished aprotocol foreﬃcientsiRNA-
mediated prolonged gene silencing in AFS cells [21]. This
protocol, which we already tested for a variety of diﬀerent
genes, allows a 96–98% downregulation of the endogenous
gene expression over a time period of about 14 days in AFS
cells and in a variety of other primary, immortalized, or
transformed cells [21].
More recently, we have made use of this approach to
study the role of the mTOR pathway in human AFS cells.
Deregulation of upstream regulators of mTOR, such as, for
example, Wnt, Ras, TNF-α, PI3K, or Akt, is a hallmark
in many human cancers. Mutations in the mTOR pathway
component genes TSC1, TSC2, LKB1, PTEN, VHL, NF1,
and PKD1 trigger the development of the human genetic
syndromes: tuberous sclerosis, the Peutz-Jeghers syndrome,
the Cowden syndrome, the Bannayan-Riley-Ruvalcaba syn-
drome, the Lhermitte-Duclos disease, the Proteus syndrome,
the von Hippel-Lindau disease, neuroﬁbromatosis type 1,
and polycystic kidney disease. Beside a variety of single-
gene disorders and tumorigenesis, the mTOR pathway has
also been shown to be of relevance for the development
of complex diseases, such as cardiac hypertrophy, obesity,
or type 2 diabetes. All these pathological consequences
of deregulated mTOR activity are explainable, considering
that mTOR is the key component of the insulin signalling
c a s c a d e ,w h i c hi si n v o l v e di naw i d ev a r i e t yo fd i ﬀerent
processes such as cell growth, proliferation, metabolism,
transcription, translation, survival, autophagy, aging, diﬀer-
entiation, and oncogenesis [8, 20, 21, 28, 32]. We found
that the entire process of embryoid body formation of AFS
cells depends on both mTOR-containing enzymes, mTORC1
and mTORC2 [20]. As mentioned above, modulating mTOR
components via speciﬁc siRNA approaches revealed that
the potential of AFS cells to contribute to renal tissue
formation is regulated by this signalling pathway [28]. More
recently, the approach to knock-down endogenous gene
functions in AFS cells allowed us to detect that the two
mTOR regulators, tuberin and PRAS40, are antiapoptotic
gatekeepersduringearlyhumanAFScelldiﬀerentiation[32].
Taken together, we strongly believe the approach of siRNA-
mediated knockdown of endogenous gene expression in
monoclonal human AFS cell lines to be a very powerful tool
for future projects dealing with the molecular regulation of
diﬀerentiation [3, 8].
Another very interesting aspect for future basic research
is the banking of AFS cell lines carrying naturally occur-
ring mutations, which are of relevance for certain human
pathological phenotypes. In medical genetics the future
development of new prophylactic and therapeutic strate-
gies directly depends on a better understanding of the
mechanisms by which naturally occurring genetic variation
contributes to disease [33]. In countries, where it is legal
to use human embryos for research, ES cell lines carrying
certain inherited defects are generated from embryos with all
kinds of numerical chromosomal abnormalities or speciﬁc
monogenic disease mutations excluded from transfer into
the uterus after preimplantation genetic diagnosis [34].
Also a variety of iPS lines from single-gene disorders,
chromosome syndromes, and complex diseases have already
been generated, with the aim to use them for basic research
projects[35].Still,asalreadydiscussedindetail,bothEScells
and iPS cells harbour relevant disadvantages compared to
AFS cells. Beside other invasive approaches, amniocentesis is
a widely accepted standard procedure of prenatal care since
the 1970s. It is almost unpredictable how many amniocen-
teses are worldwide performed per year. Taken together, we
believe that generation and banking of normal human AFS
celllinesandofAFScelllineswithchromosomalaberrations,
as well as of AFS cell lines with speciﬁc monogenic disease
mutations could provide very powerful tools for disease
modelling in future research. Here it is important to note
that banking of AFS cells for non-research purposes, with
the aim to protect a child’s health by having stem cells
available throughout his or her lifetime, is something else.
Some companies in Europe and the USA are already oﬀering
to bank AFS cells, when, for example, an amniocentesis is
performed for prenatal diagnosis. Their arguments for the
preservation of AFS cells are that these cells once could
help treating injuries (e.g., repairing cartilage for the knee),
healing wounds, or developing skin for speciﬁc grafts. As
mentioned earlier, in future, extensive research is required
to establish the putative clinical use of AFS stem cells in
humans. The promising results obtained during the last few
years within this still young scientiﬁc ﬁeld clearly warrant
further detailed investigations into the direction of putative
clinical application of AFS cells. In this paper we would
like to emphasize that banking of AFS cells with natural
occurring mutations for human genetic research should
have started as soon as possible in diﬀerent laboratories
under comparable high-quality standards. It would be worth
to encourage diﬀerent laboratories to sample amniotic
ﬂuid from amniocentesis with comparable indications from
similar weeks of pregnancy. The protocols to isolate stemStem Cells International 5
cells, perform minimal dilutions, and characterize the so-
obtained monoclonal AFS cell lines should be standardized.
Biobanking of AFS cell lines with characterized mutations
would allow to jump to the next step of human genetic
research using human stem cells [3, 8].
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